Clinical Trials for Kidney (Renal) Cancer
8 Open Trials
| Trial Type | Protocol No. & Open Date | Summary |
|---|---|---|
| Therapeutic | VICCURO12110 05/02/2013 | An International Phase 3 Randomized Trial of Autologous Dendritic Cell Immunotherapy (AGS-003) Plus Standard Treatment of Advanced Renal Cell Carcinoma (ADAPT) |
| Therapeutic | ECOGUROS0931 03/12/2013 | EVEREST: EVErolimus for Renal Cancer Ensuing Surgical Therapy, A Phase III Study |
| Therapeutic | ECOGUROS1107 03/08/2013 | Parallel (Randomized) Phase II Evaluation of ARQ 197 and ARQ 197 in Combination with Erlotinib in Papillary Renal Cell Carcinoma |
| Therapeutic | VICCURO1264 10/17/2012 | A Randomized, Open-Label, Phase 3 Study of BMS-936558 vs. Everolimus in Subjects with Advanced or Metastatic Clear-Cell Renal Cell Carcinoma Who Have Received Prior Anti-Angiogenic Therapy |
| Therapeutic | VICCMD1188 06/08/2012 | An Open-Label, Phase II Study of Vemurafenib in Patients with BRAF V600 Mutation-Positive Cancers |
| Therapeutic | VICCURO1088 08/15/2011 | A Randomized, Double-Blind, Placebo-Controlled Phase III Study to Evaluate the Efficacy and Safety of Pazopanib as Adjuvant Therapy for Subjects with Localized or Locally Advanced RCC Following Nephrectomy |
| Therapeutic | VICCURO1032 12/10/2010 | A Randomized Phase II Study of Afinitor (RAD001) vs. Sutent (Sunitinib) in Patients with Metastatic Non-Clear Cell Renal Cell Carcinoma (ASPEN) |
| Screen, Detect, Diagnose | VICCMD1286 12/17/2012 | Screening Protocol to Detect BRAF V600 Mutation Positive Patients for Enrollment into Clinical Research Studies of Vemurafenib |
You do not have JavaScript enabled. This site works better with JavaScript turned on.
